CA
GMAB icon

Continuum Advisory’s Genmab GMAB Stock Holding History

Continuum Advisory’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.06K Buy
+257
New +$6.83K ﹤0.01% 1370
2025
Q2 		– Sell
-27
Closed -$529 – 858
2025
Q1 		$529 Sell
27
-19
-41% -$399 ﹤0.01% 1572
2024
Q4 		$960 Buy
46
+1
+2% +$22 ﹤0.01% 1627
2024
Q3 		$953 Buy
45
+27
+150% +$722 ﹤0.01% 1631
2024
Q2 		$452 Hold
18
– – ﹤0.01% 1615
2024
Q1 		$519 Buy
+18
New +$529 ﹤0.01% 1598

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Continuum Advisory's GMAB Position: Q2 2026 in Review

Continuum Advisory opened a new position in Genmab (GMAB) in Q2 2026: 257 shares worth $7.06K. The stake represents ﹤0.01% of the portfolio and ranks #1370 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in GMAB as recently as Q1 2025.

Continuum Advisory first reported a position in GMAB in Q1 2024 and has held it in 6 quarters since. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Continuum Advisory held 257 shares of Genmab worth $7.06K as of Q2 2026.
  • Genmab was a new Continuum Advisory position in Q2 2026.
  • Genmab made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1370 holding.
  • Continuum Advisory first reported a position in Genmab in Q1 2024 and has held it in 6 quarters since.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.